NYSE$CHE

Chemed Corp · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Chemed's Q4 2022 financial performance reflected revenue growth and increased earnings per share.

Chemed Corporation reported a 1.0% increase in revenue to $547 million for Q4 2022. GAAP diluted EPS was $4.13, and adjusted diluted EPS increased by 2.7% to $5.39. The VITAS segment experienced a revenue decline, while Roto-Rooter showed revenue growth.

  • Consolidated revenue increased by 1.0% to $547 million.
  • GAAP diluted Earnings-per-Share (EPS) was $4.13.
  • Adjusted Diluted EPS increased by 2.7% to $5.39.
  • Roto-Rooter's revenue increased by 6.1% to $239 million.

Headline financials

Total Revenue

$547M

Previous: $541M+1.0%
EPS (adj)

$5.39

Previous: $5.25+2.7%
Average Daily Census

17.4K

Previous: 17.9K-2.8%
VITAS Admissions

14.8K

Previous: 16.3K-8.7%
Capital Expenditures

$18.3M

Previous: $14.2M+28.6%
Free Cash Flow

$81.9M

Previous: $49.4M+66.0%
Net Income

$62.1M

Previous: $74.6M-16.7%
Operating Income

$81.3M

Previous: $98M-17.0%
Gross Profit

$197M

Previous: $205M-3.7%
Cash & Equivalents

$74.1M

Previous: $33M+124.6%
Total Assets

$1.44B

Previous: $1.34B+7.4%

Revenue & EPS history

Chemed · Revenue · Quarterly

$547M

Q4 2022+1%vs Q4 2021
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Chemed · $547M total across 2 segments · Q4 2022

  • VITAS Healthcare
    $308M-2.5%
  • Roto-Rooter
    $239M+6.2%

Forward guidance

Chemed provided guidance for 2023, estimating increased revenue for both VITAS and Roto-Rooter, and provided an earnings per share range.

Tailwinds

  • VITAS 2023 revenue is estimated to increase 6.0% to 7.0%.
  • VITAS ADC is estimated to increase 3.5% to 4.0%.
  • Roto-Rooter is forecasted to achieve full-year 2023 revenue growth of 5.0% to 5.5%.
  • Roto-Rooter’s adjusted EBITDA margin for 2023 is expected to be 29.3% to 29.5%.
  • Full-year 2023 earnings per diluted share is estimated to be in the range of $20.75 to $21.10.

Headwinds

  • VITAS forecasted revenue growth is negatively impacted by 75-basis points due to sequestration relief comparison.
  • Majority of VITAS census growth expected in the second half of 2023.
  • VITAS full year adjusted EBITDA margin is estimated to be 16.3% to 16.6%.
  • Estimated $11 million for Medicare Cap billing limitations in calendar year 2023.
  • Current 2023 guidance assumes an effective corporate tax rate on adjusted earnings of 25.1%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+0.7%

Avg return

Earnings day

+0.9%

Avg return

5 days after

+2.1%

Avg return

30 days after

53%

36 / 68 earnings

Positive

+13.0%

Q3 2015

Best reaction

-14.8%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-0.1%+4.0%
Q4 2025-14.8%-9.1%-21.0%
Q3 2025+6.0%+0.4%+0.1%
Q1 2025-6.6%-1.8%-2.7%
Q4 2024+7.4%+7.7%+11.0%
Q3 2024-12.0%-12.7%-6.2%
Q2 2024-0.1%+2.4%+5.7%
Q1 2024-7.0%-8.1%-9.9%
Q4 2023+5.1%+2.6%+7.3%
Q3 2023+9.3%+10.9%+14.4%
Q2 2023-8.1%-8.0%-10.8%
Q1 2023-3.7%-2.2%-4.1%
Q4 2022+3.3%+1.7%+1.9%
Q3 2022+3.2%+4.1%+12.6%
Q2 2022-6.8%-9.2%-8.3%
Q1 2022-1.4%-1.0%+0.8%
Q4 2021+5.1%+5.8%+3.8%
Q3 2021+9.2%+9.0%+9.4%
Q2 2021-4.4%-0.4%-2.4%
Q1 2021+1.5%+2.3%+6.1%
Q4 2020-0.8%-6.7%-3.9%
Q3 2020+1.2%+3.5%+0.2%
Q2 2020+9.0%+10.3%+12.2%
Q1 2020-3.9%-6.5%+5.6%
Q4 2019+3.2%-1.2%-23.1%
Q3 2019-1.7%+0.6%+5.9%
Q2 2019+3.7%+8.1%+13.9%
Q1 2019-0.6%+0.7%+0.3%
Q4 2018+1.3%+2.8%+1.9%
Q3 2018+6.2%+6.6%+7.6%
Q2 2018+0.4%-2.5%+0.1%
Q1 2018+3.0%+3.3%+13.4%
Q4 2017+2.4%+2.1%+12.9%
Q3 2017+9.1%+5.0%+12.7%
Q2 2017-1.1%-2.3%-6.3%
Q1 2017+10.0%+9.4%+9.0%
Q4 2016+1.9%+2.0%+9.1%
Q3 2016-0.3%+1.8%+6.3%
Q2 2016+5.0%+3.0%-7.9%
Q1 2016-6.7%
Q4 2015-5.6%
Q3 2015+13.0%
Q2 2015+5.1%
Q1 2015-4.7%
Q4 2014+7.5%
Q3 2014-1.2%
Q2 2014+4.3%
Q1 2014-3.3%
Q4 2013+10.5%
Q3 2013-5.2%
Q2 2013-7.3%
Q1 2013+3.4%
Q4 2012+4.9%
Q3 2012-2.0%
Q2 2012+5.1%
Q1 2012+2.9%
Q4 2011+0.0%
Q3 2011+1.5%
Q2 2011-5.8%
Q1 2010-2.6%
Q1 2011+1.8%
Q4 2008-1.6%
Q4 2010-1.6%
Q3 2009+1.4%
Q3 2010+1.4%
Q2 2010-0.9%
Q2 2009-0.9%
Q4 2009-0.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro